This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2021-22. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of July 17, 2022, it was estimated that around every person aged 75 to 79 years of age in England had received at least two doses of a COVID-19 vaccine. Although the source does mention that this is likely to be an overestimation due to population figures taken from 2020. The data shows that at least a quarter of men under 30 years of age have not yet had two vaccine doses, with women more likely to be vaccinated among younger age groups.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Childhood Vaccination Coverage Statistics- England 2017-18 [NS] The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood vaccination coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs). Information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through PHE's ImmForm system.

Vaccination rates and odds ratios by socio-demographic group among people living in England.

Update 23 December 2019. NHS Digital have been made aware of an error in the csv version of Table 5b which previously contained data relating to Table 5c, the data contained within the file was labelled as 5c. This incorrect csv file has now been replaced. Please note that this error did not affect the Excel data file which contained the correct data. The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood immunisation coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs). Information on children aged 2, 3 and 4 immunised against seasonal flu are collected from GPs through PHE's ImmForm system. The 2016-17 report is accompanied by a new interactive data dashboard which has been developed in collaboration with Public Health England.. To access the dashboard and its functionality, one of the following internet browsers is required • Microsoft Edge • Internet Explorer 11 or later • Chrome desktop latest version • Safari Mac latest version • Firefox desktop latest version This tool is in Microsoft PowerBI which does not fully support all accessibility needs. If you need further assistance, please contact us for help.

The MMR vaccine in the United Kingdom is a combined vaccine which immunizes against measles, mumps and rubella. In 2023/24, 85.6 percent of children in Scotland had received the second dose of the vaccine by their fifth birthday, compared to 83.9 percent of children in England. Rise of measles in recent years In 2018, there were 989 cases of measles in England and Wales, this was the highest number of annual recorded cases since 2013. From 2000 to 2019, cases of measles generally increased in England and Wales. Views towards vaccines in the UK In the UK most of the population believe in the safety and effectiveness of vaccines. A 2018 survey of British respondents showed that 89 percent of the population believed that vaccines are important for children to have. In the same survey question, sixteen other European countries had a higher belief in the importance of child vaccinations than the UK, compared to twenty-one other countries which scored lower than the UK.

Coronavirus (COVID-19) vaccination rates among adults who live in England, including estimates by socio-demographic characteristic and Standard Occupational Classification (SOC) 2020

The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood immunisation coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs). Information on children aged 2, 3 and 4 immunised against seasonal flu are collected from GPs through PHE's ImmForm system.

This statistic displays the share of children who received a first dose and a second dose of Measles, Mumps and Rubella (MMR) immunization in England, from 2003/04 to 2023/24. In the year 2023/24, 83.9 percent of children had received their MMR immunization by their fifth birthday.

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

Estimates of the risk of hospital admission for coronavirus (COVID-19) and death involving COVID-19 by vaccination status, overall and by age group, using anonymised linked data from Census 2021. Experimental Statistics.

Outcome definitions

For this analysis, we define a death as involving COVID-19 if either of the ICD-10 codes U07.1 (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified) is mentioned on the death certificate. Information on cause of death coding is available in the User Guide to Mortality Statistics. We use date of occurrance rather than date of registration to give the date of the death.

We define COVID-109 hospitalisation as an inpatient episode in Hospital Episode Statistics where the primary diagnosis was COVID-19, identified by the ICD-19 codes (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified). Where an individual had experienced more than one COVID-19 hospitalisation, the earliest that occurred within the study period was used. We define the date of COVID-19 hospitalisation as the start of the hospital episode.

ICD-10 code

U07.1 :

COVID-19, virus identified

U07.2:

COVID-19, virus not identified

Vaccination status is defined by the dose and the time since the last dose received

Unvaccinated:

no vaccination to less than 21 days post first dose

First dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post first dose or less than 21 days post second dose

First dose 3+ months:

more than or equal to 91 days post first dose to less than 21 days post second dose

Second dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post second dose or less than 21 days post third dose

Second dose 3-6 months:

more than or equal to 91 days post second dose to earliest of less than 182 days post second dose or less than 21 days post third dose

Second dose 6+ months:

more than or equal to 182 days post second dose to less than 21 days post third dose

Third dose 21 days to 3 months:

more than or equal to 21 days post third dose to less than 91 days post third dose

Third dose 3+ months:

more than or equal to 91 days post third dose

Model adjustments

Three sets of model adjustments were used

Age adjusted:

age (as a natural spline)

Age, socio-demographics adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status)

Fully adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status), plus health-related characteristics (disability, self-reported health, care home residency, number of QCovid comorbidities (grouped), BMI category, frailty flag and hospitalisation within the last 21 days.

Age

Age in years is defined on the Census day 2021 (21 March 2021). Age is included in the model as a natural spline with boundary knots at the 10th and 90th centiles and internal knots at the 25th, 50th and 75th centiles. The positions of the knots are calculated separately for the overall model and for each age group for the stratified model.

In 2022, the immunisation of measles in the United Kingdom remained nearly unchanged at around 89.8 percent of children aged less than one year. Still, 2022 marked the second consecutive decline of the immunisation in this industry. Find more key insights for the immunisation in countries like Denmark, Norway, and Sweden.

Flu vaccine uptake (percent) in at risk individuals aged 6 months to 65 years (excluding pregnant women), who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

According to a survey of parents of young children in England in 2022, almost 36 percent of respondents reported the roll out of the COVID-19 vaccination had made them feel that vaccines have never been more important in preventing the spread of infections and viruses. While around 39 percent of respondents said that COVID-19 had not changed their perceptions of vaccines either positively or negatively, 26 percent said the COVID-19 vaccine roll-out had made them more wary about vaccinations.

Covid vaccinations administered by local area since 8th December 2020. It includes the calculated percentage of the 12+ population who have received all required vaccinations and/or boosters.Population estimates are based on National Immunisation Management Service counts.